Li P H, Ko K L, Ho C Tk, Lau L L, Tsang R Ky, Cheung T T, Leung W K, Lau C S
Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Pokfulam, Hong Kong.
Division of Gastroenterology & Hepatology, Department of Medicine, Queen Mary Hospital, Pokfulam, Hong Kong.
Hong Kong Med J. 2017 Oct;23(5):446-53. doi: 10.12809/hkmj176229. Epub 2017 Sep 1.
Immunoglobulin G4-related disease remains an under-recognised and evolving disease. Local data are sparse and previous publications have been limited to individual case reports or case series only. We conducted this study to review the clinical features, treatment practices, and factors associated with multisystem involvement in Hong Kong. We described the clinical features and treatment modalities of the largest cohort of immunoglobulin G4-related disease in our locality thus far.
We retrospectively evaluated all patients with immunoglobulin G4-related disease between January 2003 and December 2015 in Queen Mary Hospital and combined this with patient data extracted from previous local publications. We analysed the clinical features, treatment practices, and factors associated with the number of organ systems involved.
A total of 104 patients (55 from Queen Mary Hospital and 49 from literature review) were identified. Patients were predominantly older men (mean [standard deviation] age, 61.9 [12.7] years; male-to-female ratio=3:1) and 94.4% had elevated pre-treatment serum immunoglobulin G4 levels. Hepatobiliary and pancreatic system (40.4%), salivary gland (33.7%), lymph node (29.8%), and eye (19.2%) were the most common organ systems involved. Lymphadenopathy was associated with glucocorticoid use (odds ratio=2.65; 95% confidence interval, 1.08-6.54; P=0.034). Pre-treatment serum immunoglobulin G4 levels correlated with the number of organ systems involved (β=0.347; P=0.004) and, specifically, more associated with patients having salivary gland involvement than those without (mean, 1109 mg/dL vs 599 mg/dL; P=0.012).
We identified pre-treatment serum immunoglobulin G4 to be associated with multisystem disease, especially with salivary gland involvement, highlighting its potential for disease prognostication and monitoring. Increased physician awareness and multidisciplinary efforts are required for early diagnosis and optimal management of this masquerading disease.
免疫球蛋白G4相关疾病仍是一种未得到充分认识且不断演变的疾病。本地数据稀少,以往的出版物仅限于个别病例报告或病例系列。我们开展这项研究以回顾香港地区免疫球蛋白G4相关疾病的临床特征、治疗方法以及与多系统受累相关的因素。我们描述了迄今为止本地最大队列的免疫球蛋白G4相关疾病的临床特征和治疗方式。
我们回顾性评估了2003年1月至2015年12月在玛丽医院就诊的所有免疫球蛋白G4相关疾病患者,并将其与从以往本地出版物中提取的患者数据相结合。我们分析了临床特征、治疗方法以及与受累器官系统数量相关的因素。
共识别出104例患者(55例来自玛丽医院,49例来自文献回顾)。患者以老年男性为主(平均[标准差]年龄为61.9[12.7]岁;男女比例为3:1),94.4%的患者治疗前血清免疫球蛋白G4水平升高。肝胆胰系统(40.4%)、唾液腺(33.7%)、淋巴结(29.8%)和眼部(19.2%)是最常受累的器官系统。淋巴结病与使用糖皮质激素有关(比值比=2.65;95%置信区间为1.08 - 6.54;P = 0.034)。治疗前血清免疫球蛋白G4水平与受累器官系统数量相关(β = 0.347;P = 0.004),具体而言,与有唾液腺受累的患者相比,无唾液腺受累患者的血清免疫球蛋白G4水平更高(平均值分别为1109 mg/dL和599 mg/dL;P = 0.012)。
我们发现治疗前血清免疫球蛋白G4与多系统疾病相关,尤其是与唾液腺受累有关,突出了其在疾病预后评估和监测中的潜力。对于这种具有伪装性的疾病,需要提高医生的认识并进行多学科协作以实现早期诊断和最佳管理。